Biosimilars – Forecast – Forecast Methodology and General Market Assumptions

In 2022, sales of branded biologics for oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology indications exceeded $150 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Sales of biosimilars in these therapy areas and countries totaled approximately $13 billion. Throughout our 2022-2032 forecast period, increasing numbers of branded biologics are set to lose patent protection, and we expect biosimilars to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by therapeutic area, molecule, and country / region.

launch Related Market Assessment Reports